The Prostacyclin Analog, Treprostinil Sodium, Provides Symptom Relief in Severe Buerger’s Disease
- 1 January 2006
- journal article
- case report
- Published by SAGE Publications in Angiology
- Vol. 57 (1), 99-102
- https://doi.org/10.1177/000331970605700114
Abstract
Buerger’s disease (thromboangiitis obliterans or TAO) is a clinical syndrome characterized by the development of segmental thrombotic occlusions of the medium and small arteries. The primary treatment for Buerger’s disease is cessation of cigarette smoking. In patients whose disease progresses despite smoking cessation, therapeutic options are limited. Revascularization is rarely indicated and usually not successful because of the diffuse and distal distribution of the disease. Prostacyclin, or PGI2, and its analogs have been proposed as pharmacotherapy for Buerger’s disease and studied in Europe. The authors review the prostacyclin literature in the treatment of Buerger’s disease and present a case report of a patient with progressive Buerger’s disease and the use of treprostinil sodium (Remodulin®). This case report experience suggests that subcutaneous treprostinil therapy could be clinically useful in Buerger’s disease that does not improve with smoking cessation, particularly in the presence of critical limb ischemia where other therapeutic options have failed.Keywords
This publication has 9 references indexed in Scilit:
- Prostacyclin: A Vascular MediatorEuropean Journal of Vascular and Endovascular Surgery, 2003
- Buerger’s disease in the 21st century: diagnosis, clinical features, and therapySeminars in Vascular Surgery, 2003
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudicationVascular Medicine, 2000
- Thromboangiitis Obliterans (Buerger's Disease)New England Journal of Medicine, 2000
- Thromboangiitis obliterans:A Rare Cause of a ReversibleRaynaud’s PhenomenonDermatology, 2000
- Diagnostic criteria of Buerger's diseaseInternational Journal of Cardiology, 1998
- Cystic adventitial diseaseEuropean Journal of Vascular and Endovascular Surgery, 1998
- Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliteransThe Lancet, 1990